CytRx Corp (CYTR.OQ)
CYTR.OQ on NASDAQ Stock Exchange Capital Market
1.70USD
20 Apr 2018
1.70USD
20 Apr 2018
Change (% chg)
$-0.04 (-2.02%)
$-0.04 (-2.02%)
Prev Close
$1.74
$1.74
Open
$1.68
$1.68
Day's High
$1.73
$1.73
Day's Low
$1.66
$1.66
Volume
18,881
18,881
Avg. Vol
58,913
58,913
52-wk High
$5.99
$5.99
52-wk Low
$1.45
$1.45
About
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)
No analyst recommendations are available for .
Overall
| Beta: | 2.34 |
| Market Cap(Mil.): | $69.25 |
| Shares Outstanding(Mil.): | 165.83 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CYTR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -0.41 | -- | -- |
| ROI: | -112.76 | 1.58 | 14.38 |
| ROE: | -214.05 | 2.41 | 16.07 |
BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug Candidates
* CYTRX PRESENTS STATISTICALLY SIGNIFICANT BREAKTHROUGH DATA FOR ITS ALBUMIN BINDING ULTRA HIGH POTENCY LADR DRUG CANDIDATES
BRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials
* CYTRX SELECTS FOUR NEW LADR™ ULTRA HIGH POTENCY DRUG CANDIDATES FOR ADVANCEMENT TOWARD CLINICAL TRIALS
BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners
* CYTRX CORP - ANNOUNCED ITS ENTRY INTO A DEFINITIVE AGREEMENT WITH DESTUM PARTNERS
BRIEF-Cytrx announces new shareholder initiatives
* Cytrx Corporation provides business update and announces new shareholder initiatives
BRIEF-Cytrx reports strategic realignment of clinical development team
* Cytrx announces strategic realignment of clinical development team
BRIEF-Cytrx Corp announces reverse stock split
* Cytrx Corp- 1-for-6 reverse stock split will become effective as of commencement of trading on Wednesday, November 1, 2017 Source text for Eikon: Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Sanofi India Ltd (SANO.NS) | Rs4,998.05 | -14.15 |
| Aeolus Pharmaceuticals, Inc. (AOLS.PK) | $0.00 | -- |
| Mitsubishi Tanabe Pharma Corp (4508.T) | ¥2,092 | -9.00 |
| ONO PHARMACEUTICAL CO., LTD. (4528.T) | ¥2,482 | -0.50 |
| Oxford BioMedica plc (OXB.L) | 12.02 | +0.20 |
| IXICO PLC (IXI.L) | 35.50 | 0.00 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 6,265.00 | -67.00 |
| Amgen, Inc. (AMGN.OQ) | $171.56 | -1.37 |
| Biogen Inc (BIIB.OQ) | $263.02 | -3.00 |
| Cephalon, Inc. (CEPH.OQ) | -- | -- |
Earnings vs. 
Estimates